Skip to content

SVRA: Held by 4 Biotech Hedge Funds (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Start 14-Day Free Trial

Home›Companies›Savara Inc. (SVRA)

Savara Inc.

SVRA

Held by 4 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

4 funds opened new positions. Next phase3 readout (Molgramostim): Nov 2023. Short interest: 15.7% of float.

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Share

BiotechnologyCEO: Matthew PaulsIPO: 2017Website ↗

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

5.0/10

4 funds opened new positions●●

No recent insider activity●●

Phase3 readout expected Jun 2027●●

Held by 4 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Conviction + Catalyst

4 specialist funds hold SVRA with a Phase 3 in 412 days for Molgramostim (Autoimmune Pulmonary Alveolar Proteinosis)

Deerfield Management RTW Investments Driehaus Capital Perceptive Advisors

Fund Holdings

4 fund convergence

Deerfield ManagementHeld 6Q ↑

RTW InvestmentsNew

Driehaus Capital

Perceptive AdvisorsNew

Position history (shares)

Deerfield Management

6Q

6 quarters

Position Trend

May 15, 2025

$22.1M

1 fund

Aug 14, 2025

$18.6M

2 funds

Nov 14, 2025

$28.4M

1 fund

Feb 17, 2026

$132.2M

3 funds

+382% total institutional value over 6 quarters

Short Interest

High short interestSI rising 2 periods (+23.5%)

Short Shares

27.67M

Change

+17.7%

Days to Cover

14.6

% of Float

15.7%

Settlement

Apr 15, 2026

Short interest over 5 periods

Catalysts

Phase 3Q4 2023MolgramostimAutoimmune Pulmonary Alveolar ProteinosisNCT04544293

Phase 3Q2 2027MolgramostimAutoimmune Pulmonary Alveolar ProteinosisNCT06431776

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13G/AEcoR1 Capital5.3%Feb 14, 2022

SC 13G/AEcoR1 Capital5.3%Feb 16, 2021

SC 13G/AEcoR1 Capital5.3%Feb 12, 2021

SC 13GEcoR1 Capital8.3%Jan 6, 2020

Position Details

Deerfield ManagementINCREASEFeb 17, 2026

Start free trialfor share counts, dollar values & AI analysis

10 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

ASND1 fund IRD1 fund SLDB1 fund SYRE1 fund TNGX1 fund NBIX1 fund NRIX1 fund NUVL1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: